Skip to main content
Lupin Ltd logo

Lupin Ltd — Investor Relations & Filings

Ticker · LUPIN ISIN · INE326A01037 LEI · 335800HHXTESDEE2FC65 BSE.NS Manufacturing
Open in API
Filings indexed 3,166 across all filing types
Latest filing 2025-09-20 Regulatory Filings
Country IN India
Listing BSE.NS LUPIN

About Lupin Ltd

https://www.lupin.com/

Lupin Ltd is a global pharmaceutical organization specializing in the development, manufacturing, and marketing of a comprehensive range of generic and branded formulations, biotechnology products, and active pharmaceutical ingredients. The company holds a significant market position in therapeutic segments such as cardiovascular, diabetology, asthma, pediatrics, gastrointestinal, anti-infectives, and non-steroidal anti-inflammatory drugs. It is notably recognized for its leadership in the anti-tuberculosis medication sector. With a strong emphasis on research and development, Lupin focuses on complex generics, specialty medicines, and biosimilars. The company operates advanced manufacturing facilities and maintains a substantial commercial presence across major global markets, including North America, Europe, and the Asia-Pacific region, delivering affordable and high-quality healthcare solutions.

Recent filings

Filing Released Lang Actions
U.S. FDA has conducted a product-specific Pre-Approval Inspection at the Company''s Pune Biotech facility.
Regulatory Filings
2025-09-20 English
General Updates
Regulatory Filings Classification · 95% confidence The document is a disclosure pursuant to Regulation 30 of the SEBI Listing Regulations, informing about a U.S. FDA Pre-Approval Inspection at the company's facility and the resulting observations. It is a regulatory announcement about an event affecting the company, not a financial report, earnings release, or management discussion. The document is short (1856 characters) and serves as a compliance disclosure rather than a detailed report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-09-20 English
Lupin Receives Approval from U.S. FDA for Lenalidomide Capsules.
Regulatory Filings
2025-09-17 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing the receipt of U.S. FDA approval for Lupin Limited's Abbreviated New Drug Application for Lenalidomide Capsules. It is addressed to stock exchanges and regulatory bodies under SEBI regulations, indicating it is a disclosure announcement. The content focuses on the approval news and product details, without any financial statements, management discussion, or detailed report data. The document length is 4254 characters, which is relatively short and typical for a press release. There is no indication that this is a full financial report, earnings release, or regulatory filing beyond the announcement. Therefore, this document fits best as a Regulatory Filing (RNS) since it is a general regulatory announcement and disclosure under listing obligations, not a financial report or other specific filing type.
2025-09-17 English
U.S. FDA has conducted an inspection of Company''s Injectable facility at Nagpur.
Regulatory Filings
2025-09-16 English
General Updates
Regulatory Filings Classification · 95% confidence The document is a disclosure pursuant to Regulation 30 of the SEBI Listing Regulations, informing about a U.S. FDA inspection at Lupin's facility and the resulting observations. It is a regulatory announcement about compliance and inspection results, not a financial report, earnings release, or management discussion. The document is short (1828 characters) and serves as a regulatory update rather than a detailed report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-09-16 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.